---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-021613"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T22:58:34.688640+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics raises $1M in private placement, increases share pool by 5.5M

## Summary
- Entered securities purchase agreement for $1M private placement; initial closing of $125K at $0.60/share.
- Investor may purchase up to $875K in additional closings through Sept 25, 2026, with common warrants at $1.00/share.
- Board approved 5.5M share increase in 2014 stock incentive plan pool, now totaling ~8.4M shares.
- Proceeds from private placement to be used for working capital.

## SEC filing metadata
- accession: 0001104659-26-021613
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/0001104659-26-021613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/tm267482d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-021613
- JSON: https://secwatch.observer/filing/0001104659-26-021613.json
- Plain text: https://secwatch.observer/filing/0001104659-26-021613.txt

## Source-grounded claims
- claim_id: 16a7b68240e7fac6cfc27c14c29d9eff0680b9ff
  claim: BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with an accredited investor valued at $1,000,000 (effective 2026-02-24).
  evidence_excerpt: On February 24, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ). The transaction will occur in up to eight closings. The aggregate subscription amount under the Purchase Agreement is $1,000,000, consisting of $125,000 at the first closing and an additional $875,000 on up to seven additional closings.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/0001104659-26-021613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.